Valuation: Talphera, Inc.

Market Cap 66.43M 57.74M 53.9M 49.48M 93.3M 6.33B 94.93M 636M 249M 3.16B 250M 244M 10.42B P/E 2026 *
-5.12x
P/E 2027 * -4.57x
Enterprise Value 66.43M 57.74M 53.9M 49.48M 93.3M 6.33B 94.93M 636M 249M 3.16B 250M 244M 10.42B EV / Sales 2026 *
-
EV / Sales 2027 * 332x
Free-Float
78.58%
Yield 2026 *
-
Yield 2027 * -
1 day+3.91%
1 week+5.56%
Current month+3.91%
1 month+12.71%
3 months+49.35%
6 months+52.19%
Current year+16.67%
1 week 1.22
Extreme 1.22
1.41
1 month 1
Extreme 1
1.5
Current year 0.69
Extreme 0.6866
1.5
1 year 0.39
Extreme 0.3862
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
25
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 2017-03-05
Director of Finance/CFO 56 2017-07-31
Chief Tech/Sci/R&D Officer - 2024-09-30
Director TitleAgeSince
Director/Board Member 60 2006-07-31
Director/Board Member 72 2010-01-31
Chairman 75 2013-02-10
Date Insider Type Main position Quantity % Market Cap.
4/2/26 Tax

Chief Technology Officer

2,118 0.0042%
2/12/26 Buy

Chief Technology Officer

240,000 0.5149%
2/10/26 Tax

Chief Technology Officer

238,127 0.5109%
Change 5-day change 1-year change 3-year change Capi.($)
+3.91%+5.56%+230.02%+29.13% 66.43M
-1.87%-2.29%+59.99%+20.85% 322B
-0.49%+2.37%+32.94%-10.44% 71.6B
-0.33%+0.97%+37.14%+95.42% 9.79B
-1.53%-3.92%-2.67%-7.72% 8.39B
-0.76%-2.73%-16.42%-13.85% 4.3B
+0.14%-1.74%-34.69%+6.15% 3.81B
-2.35%-3.72%-14.99%+13.09% 3.58B
+3.07%-2.09%+24.16%+44.43% 2.59B
+0.47%+10.40%+0.22%-2.76% 2.25B
Average +0.08%-0.12%+31.57%+17.43% 42.8B
Weighted average by Cap. -1.38%-0.03%+50.97%+16.23%

Financials

2026 *2027 *
Net sales - 200K 174K 162K 149K 281K 19.06M 286K 1.91M 749K 9.51M 751K 735K 31.36M
Net income -17.96M -15.61M -14.58M -13.38M -25.23M -1.71B -25.67M -172M -67.32M -854M -67.48M -65.98M -2.82B -20.15M -17.51M -16.35M -15.01M -28.29M -1.92B -28.79M -193M -75.49M -958M -75.67M -73.99M -3.16B
Net Debt - -
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
26-08-03 US$1.330 +3.91% 120,266
26-07-31 US$1.280 -5.54% 197,348
26-07-30 US$1.355 +3.44% 71,056
26-07-29 US$1.310 +0.77% 132,940
26-07-28 US$1.300 +3.17% 147,963
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.280USD
Average target price
3.167USD
Spread / Average Target
+147.40%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TLPH Stock